Any current/future new fundraising through debt or equity?

The company has completed a preferential allotment, expecting to raise around ₹189 crores through QIP (Qualified Institutional Placement). The preferential allotment was approved in the General Board meeting and Annual General Meeting at the end of September. Filing with authorities has been done in the first week of October, and approval is expected by November with 25% payment to be received within 15 days post-approval. The funds raised will be primarily used for expanding backward integration in technicals and intermediates (₹80-90 crores) and the balance for working capital (₹110-12

Any current/future capex/capital investment/strategic investment?

Planned CapEx of around ₹80-90 crores funded through preferential allotment, focused on backward integration for technicals and intermediates. CapEx execution expected in multiple phases, with completion within 6 to 9 months (~2-3 quarters). The CapEx involves brownfield expansion, with plant trials and stabilization anticipated by Q1-Q2 FY26. Future growth planning for additional CapEx will be considered after current project completion. Development of a production facility for herbicides and patented formulations for international markets is in progress (timeline 1-3 years depending on regis

Future growth expectations in sales/revenue/volumes?

The company targets revenues of ₹450 crore per quarter in upcoming quarters, achievable through specialty molecule sales rather than generics. Management confidently expects over 100% volume growth in Q3 and Q4 to achieve these revenue targets. FY25 topline guidance indicates at least 15-16% growth, aiming to cross ₹2,100 crore in revenue. FY26 growth is expected to be around 20% driven by new patented product launches and market expansion. New product launches each year (2-3) include patented herbicides, fungicides, and insecticides to sustain growth. Southern market penetration and

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects at least 15-16% top-line revenue growth for FY25, with revenues anticipated to exceed ₹2,000 crores, potentially crossing ₹2,100 crores. For FY26, management projects around 20% growth in top line. EBITDA margins are expected to improve, supported by focus on patented molecules and branded products, with recent gross margin expansion from 26% to 34% YoY. B2C business, with higher gross margins (~40-45%) compared to B2B (20-25%), is set to increase its revenue share, improving overall profitability. PAT margins have improved to around 13% in Q2 FY25, with expectation

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a current or expected order book or pending orders in quantitative terms. However, Management highlighted a strong demand outlook, particularly for the upcoming Rabi season, expecting good numbers in Q3 and Q4. There is confidence in achieving more than 2100 crores revenue in FY25, driven by specialty patented products and new herbicides like "Shot Down," indicating a healthy sales pipeline. Inventory levels remain high (873 crores as of September) but largely liquidated, and SAP implementation has improved visibility on channel inventory and liquidat

Best AgrolifeQ2 FY25Fertilizers & Agrochemicals

Best Agrolife Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹17.5P/E: 21.9Market Cap: ₹647 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company targets revenues of ₹450 crore per quarter in upcoming quarters, achievable through specialty molecule sales rather than generics.
Management confidently expects over 100% volume growth in Q3 and Q4 to achieve these revenue targets.
FY25 topline guidance indicates at least 15-16% growth, aiming to cross ₹2,100 crore in revenue.
FY26 growth is expected to be around 20% driven by new patented product launches and market expansion.
New product launches each year (2-3) include patented herbicides, fungicides, and insecticides to sustain growth.
Southern market penetration and an improved understanding of regional dynamics bolster confidence in growth.
International business development is progressing, but registrations may take 1-6 years; focus is on patented molecules to compete globally, especially against China.
Transition towards a B2C brand model (Sudarshan and Best Agro) by FY27 aims to increase margins and overall sales.

Margin guidance

Category 1

The company expects at least 15-16% top-line revenue growth for FY25, with revenues anticipated to exceed ₹2,000 crores, potentially crossing ₹2,100 crores.
For FY26, management projects around 20% growth in top line.
EBITDA margins are expected to improve, supported by focus on patented molecules and branded products, with recent gross margin expansion from 26% to 34% YoY.
B2C business, with higher gross margins (~40-45%) compared to B2B (20-25%), is set to increase its revenue share, improving overall profitability.
PAT margins have improved to around 13% in Q2 FY25, with expectations of continued profit growth aligned with top-line expansion.
New product launches (patented herbicide "Shot Down" and innovative insecticides) in Q3 and Q4 FY25 are expected to drive further revenue and profit growth.
Improvement in return provisions and inventory management through SAP implementation may positively impact earnings in upcoming quarters.

See what Best Agrolife management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company has completed a preferential allotment, expecting to raise around ₹189 crores through QIP (Qualified Institutional Placement).
The preferential allotment was approved in the General Board meeting and Annual General Meeting at the end of September.
Filing with authorities has been done in the first week of October, and approval is expected by November with 25% payment to be received within 15 days post-approval.
The funds raised will be primarily used for expanding backward integration in technicals and intermediates (₹80-90 crores) and the balance for working capital (₹110-120 crores).
No mention of new debt fundraising was made; the company reported an improved debt-to-equity ratio from 0.90 to 0.59 as of September 2024.

Order book

The transcript does not explicitly mention a current or expected order book or pending orders in quantitative terms.
However, Management highlighted a strong demand outlook, particularly for the upcoming Rabi season, expecting good numbers in Q3 and Q4.
There is confidence in achieving more than 2100 crores revenue in FY25, driven by specialty patented products and new herbicides like "Shot Down," indicating a healthy sales pipeline.
Inventory levels remain high (873 crores as of September) but largely liquidated, and SAP implementation has improved visibility on channel inventory and liquidation.
The company is focusing on expanding in southern markets and international registrations, which could contribute to future order flow.
Overall, while exact order book figures are not stated, the optimistic sales guidance and inventory strategies suggest a strong pending order pipeline for H2 FY25 and beyond.

See what Best Agrolife management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned CapEx of around ₹80-90 crores funded through preferential allotment, focused on backward integration for technicals and intermediates.
CapEx execution expected in multiple phases, with completion within 6 to 9 months (~2-3 quarters).
The CapEx involves brownfield expansion, with plant trials and stabilization anticipated by Q1-Q2 FY26.
Future growth planning for additional CapEx will be considered after current project completion.
Development of a production facility for herbicides and patented formulations for international markets is in progress (timeline 1-3 years depending on registration).
Strategic incorporation of a China subsidiary to boost collaborative R&D and enhance supplier cooperation.
Overall investments aim at improving operational efficiency, expanding product portfolio, and strengthening market competitiveness worldwide.

Track Best Agrolife — get its next earnings analysis in your feed

How does Best Agrolife rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisBest Agrolife

Rev 3Mar 1

See where Best Agrolife sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Best Agrolife rank in Fertilizers & Agrochemicals?

Compare Best Agrolife against every Fertilizers & Agrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Best Agrolife's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Advance Agrolife Ltd (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
Advance Agrolife Ltd (Q1 FY27)
Q1 FY27 revenue from operations: ₹3,304 million, a 96% year-on-year (YoY) increase (Page 23, 25, 22). Key concall takeaways from Advance Agrolife Ltd's Q1 FY27…
Bhagiradha Chemicals & Industries Ltd (Q4 FY26)
158.1 crores . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
Bhagiradha Chemicals & Industries Ltd (Q1 FY27)
195.0 crore . Key concall takeaways from Bhagiradha Chemicals & Industries Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →